Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
1.440
-0.030 (-2.04%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.
Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Boundless Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Zachary Hornby |
Contact Details
Address: 10955 Alexandria Way, Suite 100 San Diego, California 92121 United States | |
| Phone | 858 766 9912 |
| Website | boundlessbio.com |
Stock Details
| Ticker Symbol | BOLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001782303 |
| CUSIP Number | 10170A100 |
| ISIN Number | US10170A1007 |
| Employer ID | 83-0751369 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zachary Hornby | Chief Executive Officer, President and Director |
| Dr. Christian Hassig Ph.D. | Chief Scientific Officer |
| David Hinkle | Senior Vice President of Finance, Controller and Corporate Treasurer |
| Jessica Oien J.D. | Chief Legal Officer and Corporate Secretary |
| Meredith Wesley | Chief Human Resources Officer |
| Amy Berkley Ph.D. | Senior Vice President of Program Team |
| Dr. James L. Freddo M.D. | Interim Chief Medical Officer |
| Dr. Robert C. Doebele M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 13, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 10-K | Annual Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Dec 4, 2025 | SCHEDULE 13G | Filing |
| Nov 5, 2025 | 10-Q | Quarterly Report |